Bioxytran Reports Q1 2025 Results: Reduced Expenses Amid Rising Losses and Liabilities

Bioxytran, Inc. (PINK: BIXT) recently released its financial results for the first quarter ended March 31, 2025. Here are the key highlights and insights based on the income statement.

Positive Aspects:

• Reduction in Total Operating Expenses: Total operating expenses decreased to $515,142 from $779,229 in the same period last year, largely due to a significant reduction in general administrative costs.
• Decrease in Loss from Operations: Loss from operations reduced to $(515,142) compared to $(779,229) a year earlier, indicating improved operational efficiency.
• R&D Investment: The company invested $349,500 in research and development, up from $27,000, demonstrating its commitment to advancing its drug candidates.

Negative Aspects:

• Significant Net Loss: The net loss amounted to $(1,353,635), compared to $(560,522) in Q1 2024, primarily due to a large derivative liability change of $(804,752) resulting from market price fluctuations.
• Increased Current Liabilities: Current liabilities surged to $2,844,089 from $1,930,642, driven notably by accounts payable and derivative liabilities.
• Negative Working Capital: The company reported a negative working capital of $(2,839,741), raising concerns about liquidity and ongoing operations.

Key Financial Statistics:

• Total Current Assets: $4,348
• Total Liabilities: $2,844,089
• Accumulated Deficit: $(20,274,803)
• Loss Per Share: $(0.02)
• Weighted Average Shares Outstanding: 88,839,723

Bioxytran remains a clinical-stage pharmaceutical company focused on innovative treatments for conditions tied to hypoxia. The financials indicate an emphasis on development with significant R&D spending, but the increasing losses and liabilities need to be addressed to ensure liquidity and operational stability moving forward.